A recent meta-analysis study revealed that Asian cancer patients receiving PD-1/PD-L1 (programmed cell death 1)/(programmed death-ligand 1)-inhibitor-based therapy may experience a significantly improved benefit in terms of survival rate when compared to non-Asian patients [42]. This evidence concerns the gene CD274 and cancer.